基本説明
Special reviews in this Annual include, among other topics, Epidemiology of the use of ecstasy, Paracetamol and the risk of asthma, Combination vaccines/multiple immunizations, Interactions of herbal medicines with warfarin, and Tyrosine kinase inhibitors.
Full Description
The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.
Contents
ContributorsSpecial reviewsCumulative indexes of special reviews, Annuals 11-321 Index of drugs2 Index of adverse reactionsTable of Essays, Annuals 1-32Mechanistic and clinical descriptions of adverse drug reactions1 EIDOS2 DoTSHow to use this bookThe scope of the Side Effects of Drugs AnnualsPeriod coveredSelection of materialClassification of drugsNames of drugs and chemicalsSystem of tagging referencesIndexesAbbreviationsSide Effects Of Drugs EssayThree generationsRenewed concernProfiling the riskA fourth generation?The defendersThe view todayConclusionsChapter 1: Central nervous system stimulants and drugs that suppress appetiteAmphetamines [SED-15, 180; SEDA-30, 1; SEDA-31, 1; SEDA-32, 1]MethylxanthinesDrugs that suppress appetite [SEDA-30, 7; SEDA-31, 9; SEDA-32, 16]Drugs used in Alzheimer's disease [SEDA-30, 8; SEDA-31, 10; SEDA-32, 19]Chapter 2: Antidepressant drugsGeneralMonoamine oxidase inhibitors [SED-15, 2371; SEDA-32, 32]Selective serotonin re-uptake inhibitors (SSRIs) [SED-15, 3109; SEDA-30, 16; SEDA-31, 18; SEDA-32, 33]Serotonin and noradrenaline re-uptake inhibitors (SNRIs)Other antidepressantsChapter 3: LithiumChapter 4: Drugs of abuseCannabinoids [SED-15, 614; SEDA-30, 31; SEDA-31, 33; SEDA-32, 55]Cocaine [SED-15, 848; SEDA-30, 31; SEDA-31, 37; SEDA-32, 58]Opioid analgesicsChapter 5: Hypnosedatives and anxiolyticsAzaspirones [SEDA-28, 52; SEDA-32, 75]Benzodiazepines [SED-15, 429; SEDA-30, 49; SEDA-31, 57; SEDA-32, 75]Benzodiazepine-like drugsBenzodiazepine antagonistsOther hypnosedativesChapter 6: Antipsychotic drugsGeneral [SED-15, 2438; SEDA-32, 83]Individual drugsChapter 7: Antiepileptic drugsGeneralChapter 8: Opioid analgesics and narcotic antagonistsGeneralOpioid receptor agonistsPartial opioid receptor agonistsOpioid receptor antagonistsChapter 9: Anti-inflammatory and antipyretic analgesics and drugs used in goutAmidopyrine and related compoundsAniline derivatives [SED-15, 2679; SEDA-30, 129]Anthranilic acid derivativesArylalkanoic acid derivatives [SED-15, 2555; SEDA-31, 186; SEDA-32, 229]COX-2 selective inhibitors [SEDA-30, 130; SEDA-31, 190; SEDA-32, 232]Indoleacetic acids [SEDA-25, 134]Oxicams [SEDA-15, 2555; SEDA-28, 128; SEDA-30, 132; SEDA-32, 233]Pyrazolone derivatives (phenylbutazone and related compounds) [SEDA-27, 111]Salicylates [SED-15, 15; SEDA-30, 128]Miscellaneous drugsDrugs used in the treatment of goutChapter 10: General anesthetics and therapeutic gasesAnesthetic vapors [SEDA-30, 137; SEDA-31, 217; SEDA-32, 243]Other vaporsIntravenous agents: non-barbiturate anestheticsIntravenous agents: barbiturate anestheticsChapter 11: Local anestheticsGeneralEffects related to modes of use [SED-15, 2121; SEDA-30, 152; SEDA-31, 233; SEDA-32, 262]Caudal, epidural, and spinal anesthesiaIndividual compoundsChapter 12: Neuromuscular blocking agents and skeletal muscle relaxantsDepolarizing neuromuscular blocking agentsNon-depolarizing neuromuscular blocking agents [SED-15, 2489; SEDA-31, 248; SEDA-32, 274]Skeletal muscle relaxantsChapter 13: Drugs that affect autonomic functions or the extrapyramidal systemDrugs that stimulate both alpha- and beta-adrenoceptors [SEDA-30, 170; SEDA-31, 259; SEDA-32, 281]Drugs that predominantly stimulate alpha1-adrenoceptors [SEDA-27, 147; SEDA-30, 172; SEDA-31, 264; SEDA-32, 283]Drugs that stimulate beta1-adrenoceptors [SEDA-30, 173; SEDA-31, 265; SEDA-32, 284]Drugs that stimulate beta2-adrenoceptorsOther drugs that increase dopamine activityDrugs that affect the cholinergic system [SEDA-30, 177; SEDA-31, 272; SEDA-32, 290]Chapter 14: Dermatological drugs, topical agents, and cosmeticsCosmeticsDermal fillersDyestuffs [SEDA-15, 1573; SEDA-30, 182; SEDA-31, 288; SEDA-32, 296]FragrancesPhototherapy and photochemotherapy [SED-15, 2823; SEDA-32, 297]Vitamin A (retinoids) [SED-15, 3653; SEDA-30, 185; SEDA-32, 298; for vitamin A carotenoids see Chapter 34]Vitamin D analogues, topical [SED-15, 594; SEDA-31, 293; SEDA-32, 301; for oral Vitamin D analogues see Chapter 34]Chapter 15: Antihistamines (H1 receptor antagonists)Chapter 16: Drugs that act on the respiratory tractInhaled glucocorticoids [SEDA-30, 193; SEDA-31, 305; SEDA-32, 311]Beta2-adrenoceptor agonists [SEDA-30, 198; SEDA-31, 308; SEDA-32, 314]Anticholinergic drugs [SEDA-30, 203; SEDA-31, 311; SEDA-32, 318]Leukotriene modifiers [SEDA-30, 203; SEDA-31, 312; SEDA-32, 319]Phosphodiesterase type IV inhibitors [SEDA-29, 174; SEDA-30, 203; SEDA-31, 313; SEDA-32, 321]Lipoxygenase inhibitorsMucolytics [SEDA-32, 325]Chapter 17: Positive inotropic drugs and drugs used in dysrhythmiasCardiac glycosides [SED-15, 648; SEDA-30, 209; SEDA-31, 321; SEDA-32, 333]Other positive inotropic drugs [SED-15, 2822; SEDA-30, 212; SEDA-31, 323; SEDA-32, 336]Antidysrhythmic drugsChapter 18: Beta-adrenoceptor antagonists and antianginal drugsBeta-adrenoceptor antagonists [SED-15, 452; SEDA-30, 223; SEDA-31, 339; SEDA-32, 363]Potassium channel activatorsNitrates, organic [SEDA-15, 2529; SEDA-30, 225; SEDA-32, 366]Calcium channel blockers [SED-15, 598; SEDA-30, 225; SEDA-31, 340; SEDA-32, 366]Chapter 19: Drugs acting on the cerebral and peripheral circulationsDrugs used in the treatment of arterial disorders of the brain and limbsDrugs used in the treatment of migraineOther peripheral vasodilatorsChapter 20: Antihypertensive drugsAngiotensin converting enzyme inhibitors [SED-15, 226; SEDA-30, 234; SEDA-31, 350; SEDA-32, 379]Angiotensin ii receptor antagonists [SED-15, 223; SEDA-30, 238; SEDA-31, 358; SEDA-32, 387]Direct renin inhibitors [SEDA-30, 242; SEDA-31, 360; SEDA-32, 000]Endothelin receptor antagonists [SED-15, 1215; SEDA-30, 245; SEDA-31, 360; SEDA-32, 389]Drugs that act on the sympathetic nervous system [SEDA-30, 245; SEDA-31, 362; SEDA-32, 391]Postsynaptic -adrenoceptor antagonists [SEDA-30, 246; SEDA-31, 363; SEDA-32, 391]Imidazoline receptor agonistsOther centrally acting drugsDirect vasodilatorsChapter 21: DiureticsCarbonic anhydrase inhibitors [SED-15, 643; SEDA-30, 254; SEDA-31, 371; SEDA-32, 403]Thiazide and thiazide-like diuretics [SED-15, 3375; SEDA-30, 256; SEDA-31, 372; SEDA-32, 405]Loop diuretics [SED-15, 567, 1454; SEDA-30, 258; SEDA-31, 375; SEDA-32, 408]Aldosterone receptor antagonistsOsmotic diureticsChapter 22: MetalsChapter 23: Metal antagonistsIron chelatorsPenicillamine and related drugs [SED-15, 2729; SEDA-30, 274; SEDA-31, 403; SEDA-32, 430]Other chelatorsPolystyrene sulfonates [SED-15, 2894; SEDA-30, 275; SEDA-32, 433]Chapter 24: Antiseptic drugs and disinfectantsAldehydes [SED-15, 1439, 1513; SEDA-31, 409; SEDA-32, 437]BisbiguanidesCationic surfactantsDyestuffsHalogensIodophors [SEDA-15, 1896; SEDA-30, 279; SEDA-31, 411; SEDA-32, 440]Phenolic compounds [SED-15, 2800, SEDA-32, 441]Chapter 25: Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclinesBeta-lactam antibiotics [SED-15, 478; SEDA-30, 280; SEDA-31, 420; SEDA-32, 447]Cephalosporins [SED-15, 688; SEDA-30, 284; SEDA-31, 422; SEDA-32, 448]Monobactams and monocarbams [SED-15, 2378; SEDA-30, 286; SEDA-31, 423; SEDA-32, 450]Penicillins [SED-15, 2756; SEDA-30, 286; SEDA-31, 424; SEDA-32, 450]Tetracyclines and glycylcyclines [SED-15, 3330; SEDA-30, 288; SEDA-31, 419; SEDA-32, 451]Chapter 26: Miscellaneous antibacterial drugsAminoglycoside antibiotics [SED-15, 118; SEDA-30, 297; SEDA-31, 427; SEDA-32, 461]Chloramphenicol and related drugs [SED-15, 706; SEDA-30, 298; SEDA-31, 429; SEDA-32, 464]Fluoroquinolones [SED-15, 1396; SEDA-30, 298; SEDA-31, 429; SEDA-32, 464]Glycopeptides [SEDA-30, 435; SEDA-32, 469]Ketolides [SED-15, 1976; SEDA-30, 301; SEDA-31, 436; SEDA-32, 471]Lincosamides [SED-15, 2063; SEDA-30, 302; SEDA-31, 437; SEDA-32, 472]Macrolide antibiotics [SED-15, 2183; SEDA-30, 302; SEDA-31, 437; SEDA-32, 472]Nitrofurantoin [SED-15, 2542; SEDA-30, 303; SEDA-31, 439; SEDA-32, 476]Oxazolidinones [SED-15, 2645; SEDA-30, 304; SEDA-31, 439]Polymyxins [SED-15, 2891; SEDA-31, 441; SEDA-32, 476]Streptogramins [SED-15, 3182; SEDA-28, 285; SEDA-30, 307; SEDA-31, 442]Sulfonamides, trimethoprim, and co-trimoxazole [SED-15, 3216, 3510; SEDA-30, 308; SEDA-31, 442; SEDA-32, 477]Other antimicrobial drugsChapter 27: Antifungal drugsAllylamines [SEDA-30, 316; SEDA-31, 457; SEDA-32, 491]Amphotericin [SED-15, 192; SEDA-30, 317; SEDA-31, 458; SEDA-32, 493]Antifungal azoles [SED-15, 301; SEDA-30, 320; SEDA-31, 459; SEDA-32, 497]Echinocandins [SED-15, 1197; SEDA-30, 329; SEDA-31, 464; SEDA-32, 507]Flucytosine [SED-15, 1388; SEDA-32, 497]Chapter 28: Antiprotozoal drugsAntimalarial drugs4-Aminoquinolines (chloroquine and congeners) [SEDA-30, 336; SEDA-31, 469; SEDA-32, 521]Primaquine and congeners [SED-15, 2919]Pyrimethamine and congeners [SED-15, 2984; SEDA-32, 523]Quinine and congeners [SED-15, 3002; SEDA-31, 472; SEDA-32, 524]Endoperoxides [SED-15, 342; SEDA-30, 338; SEDA-31, 473; SEDA-32, 525]Drugs used in the treatment of Pneumocystis jirovecii infectionsDrugs used in the treatment of other protozoal infectionsMiscellaneous drugsChapter 29: Antiviral drugsEditor's notes: Interferons are covered inChapter 37.Drugs active against cytomegalovirusDrugs active against herpesviruses [SEDA-29, 301; SEDA-30, 343; SEDA-31, 478; SEDA-32, 530]Drugs active against hepatitis virusesDrugs active against human immunodeficiency virusDrugs active against human immunodeficiency virus: combinationsDrugs active against human immunodeficiency virus: nucleoside analogue reverse transcriptase inhibitors (NRTI) [SED-15, 2586; SEDA-30, 349; SEDA-31, 482; SEDA-32, 534]Drugs active against human immunodeficiency virus: nucleotide analogue reverse transcriptase inhibitorsDrugs active against human immunodeficiency virus: non-nucleoside reverse transcriptase inhibitors (NNRTI) [SED-15, 2553; SEDA-30, 349; SEDA-31, 486; SEDA-32, 537]Drugs active against human immunodeficiency virus: protease inhibitors [SED-15, 2586; SEDA-30, 351; SEDA-31, 487; SEDA-32, 541]Drugs active against human immunodeficiency virus: inhibitors of HIV fusion [SEDA-28, 337; SEDA-29, 310]Drugs active against human immunodeficiency virus: integrase inhibitorsDrugs active against human immunodeficiency virus: chemokine receptor CCR5 antagonistsDrugs active against influenza viruses: neuraminidase inhibitors [SED-15, 2436; SEDA-30, 352; SEDA-31, 489; SEDA-32, 544]Drugs active against influenza viruses: ion channel inhibitors [SED-15, 105, 3051; SEDA-31, 489; SEDA-32, 544]Chapter 30: Drugs used in tuberculosis and leprosyRifamycins [SED-15, 3040; SEDA-30, 359; SEDA-31, 498; SEDA-32, 563]Chapter 31: Antihelminthic drugsBenzimidazoles [SED-15, 424; SEDA-30, 364; SEDA-31, 508; SEDA-32, 572]Chapter 32: VaccinesGeneralBacterial vaccinesViral vaccinesOther components of vaccinesChapter 33: Blood, blood components, plasma, and plasma productsAlbumin and Derivatives [SED-15, 54; SEDA-30, 381; SEDA-31, 527; SEDA-32, 591]Anticoagulant proteins [SED-15, 266; SEDA-30, 381; SEDA-31, 527; SEDA-32, 591]Blood transfusion [SED-15, 529; SEDA-30, 381; SEDA-31, 528; SEDA-32, 593]Blood substitutes [SEDA-30, 383; SEDA-31, 531; SEDA-32, 593]Plasma and plasma products [SED-15, 2847; SEDA-30, 383; SEDA-31, 532; SEDA-32, 594]Plasma substitutes [SEDA-30, 384; SEDA-31, 533; SEDA-32, 594]GlobulinsCoagulation proteins [SED-15, 845; SEDA-30, 387; SEDA-31, 537; SEDA-32, 596]Erythropoietin and derivatives [SED-15, 1243; SEDA-30, 388; SEDA-31, 538; SEDA-32, 597]Stem cells [SEDA-30, 389; SEDA-31, 539; SEDA-32, 599]Chapter 34: Vitamins, intravenous solutions, and drugs and formulations used in nutritionVitamin A (carotenoids) [SED-15, 3642; SEDA-31, 548; SEDA-32, 607]Vitamins of the B group [SED-15, 2700; SEDA-31, 548; SEDA-32, 608]Vitamin C (ascorbic acid) [SED-15, 351; SEDA-30, 394; SEDA-31, 548; SEDA-32, 611]Vitamin D analogues [SED-15, 3669; SEDA-30, 394; SEDA-31, 549; SEDA-32, 612]Vitamin E (tocopherol) [SED-15, 3677; SEDA-30, 395; SEDA-31, 549; SEDA-32, 612]Parenteral nutrition [SED-15, 2700; SEDA-31, 549; SEDA-32, 613]Enteral nutrition [SED-15, 1221; SEDA-30, 396]Chapter 35: Drugs that affect blood coagulation, fibrinolysis, and hemostasisCoumarin anticoagulants [SED-15, 983; SEDA-30, 399; SEDA-31, 553; SEDA-32, 617]Heparins [SED-15, 1590; SEDA-30, 404; SEDA-31, 556; SEDA-32, 626]Direct thrombin inhibitors [SED-15, 1142; SEDA-30, 409; SEDA-31, 559; SEDA-32, 632]Indirect factor Xa inhibitors [SEDA-30, 412; SEDA-31, 563; SEDA-32, 636]Drugs that alter platelet function [SEDA-30, 413; SEDA-31. 564; SEDA-32, 637]Thienopyridines [SED-15, 821; SEDA-30, 415; SEDA-31, 566; SEDA-32, 639]Hemostatic agentsChapter 36: Gastrointestinal drugsAntacids [SED-15, 243; SEDA-30, 423; SEDA-31, 573; SEDA-32, 665]Antiemetics and drugs that affect gastrointestinal motility [SEDA-30, 423; SEDA-31, 573; SEDA-32, 665]5HT3 receptor antagonists [SED-15, 1365; SEDA-30, 423; SEDA-31, 575; SEDA-32, 666]Neurokinin NK1 receptor antagonists [SEDA-32, 667]Histamine H2 receptor antagonists [SED-15, 1629; SEDA-30, 423; SEDA-31, 576; SEDA-32, 667]Helicobacter pylori eradication regimens [SED-15, 1586; SEDA-30, 425; SEDA-31, 579]Proton pump inhibitors [SED-15, 2973; SEDA-30, 424; SEDA-31, 577; SEDA-32, 667]Other ulcer-healing agentsLaxatives and oral bowel preparations [SED-15, 2008; SEDA-30, 426; SEDA-31, 581; SEDA-32, 668]Aminosalicylates [SED-15, 138; SEDA-30, 428; SEDA-31, 583; SEDA-32, 669]Antispasmodic agentsAntidiarrheal agentsCholelitholytic agents, bile acidsOther gastrointestinal agentsChapter 37: Drugs that act on the immune systemColony-stimulating factors [SEDA-30, 435; SEDA-31, 589; SEDA-32, 675]Interferons [SED-15, 1841; SEDA-30, 436; SEDA-31, 591; SEDA-32, 676]Interleukins [SED-15, 1831; SEDA-30, 438; SEDA-31, 592; SEDA-32, 676]Tumor necrosis factor alfa (TNF- ) and its antagonists [SEDA-30, 439; SEDA-31, 592; SEDA-32, 677]Monoclonal antibodies [SED-15, 2380; SEDA-30, 442; SEDA-31, 602; SEDA-32, 686]Chapter 38: Drugs that act on the immune systemThiopurinesChapter 39: Corticotrophins, corticosteroids, and prostaglandinsSystemic glucocorticoids [SED-15, 906; SEDA 30, 463; SEDA-31, 651; SEDA-32, 723]Prostaglandins and analogues [SED-15, 2955; SEDA-30, 465; SEDA-31, 651; SEDA-32, 729]Chapter 40: Sex hormones and related compounds, including hormonal contraceptivesGonadotropins [SED-15, 1536; SEDA-30, 468; SEDA-31, 656; SEDA-32, 735]Estrogens [SED-15, 1253; SEDA-30, 469; SEDA-31, 657; SEDA-32, 736]Hormonal contraceptives [SED-15, 1642; SEDA-30, 473; SEDA-31, 663; SEDA-32, 741]Antiestrogens and selective estrogen receptor modulators (SERMs) [SEDA-30, 474; SEDA-31, 664; SEDA-32, 743]Progestogens [SED-15, 2930; SEDA-30, 477; SEDA-31, 669; SEDA-32, 747]Progesterone antagonists [SEDA-30, 477; SEDA-31, 671; SEDA-32, 749]Sex hormone agonistsSex hormone antagonistsAnabolic steroids, androgens, and related compounds [SED-15, 216; SEDA-30, 477; SEDA-31, 672; SEDA-32, 751]Antiandrogens [SEDA-29, 510; SEDA-30, 479; SEDA-31, 673; SEDA-32, 755]Chapter 41: Thyroid hormones, iodine, and antithyroid drugsThyroid hormones [SED-15, 3409; SEDA-30, 490; SEDA-31, 687; SEDA-32, 763]Iodine and iodides [SED-15, 1896; SEDA-30, 490; SEDA-31, 688; SEDA-32, 764]Antithyroid drugs [SEDA-15, 3387; SEDA-30, 490; SEDA-31, 689; SEDA-32, 765]Chapter 42: Insulin, other hypoglycemic drugs, and glucagonGlucagon [SED-15, 1510; SEDA-31, 689; SEDA-32, 769]Insulin [SED-15, 1761; SEDA-30, 494; SEDA-31, 689; SEDA-32, 769]Alpha-glucosidase inhibitors [SED-15, 85; SEDA-30, 496; SEDA-31, 691; SEDA-32, 772]Amylin analogues [SEDA-30, 496; SEDA-31, 692; SEDA-32, 773]Biguanides [SED-15, 506; SEDA-30, 497; SEDA-31, 692; SEDA-32, 773]Dipeptidyl peptidase 4 (DDP-4) inhibitors [SEDA-30, 498; SEDA-31, 693; SEDA-32, 774]Incretin mimetics [SEDA-30, 49; SEDA-31, 695; SEDA-32, 775]Meglitinides [SED-15, 2238; SEDA-31, 695; SEDA-32, 776]Sodium glucose transporter type 2 (SGLT2) inhibitorsSulfonylureas [SED-15, 3230; SEDA-30, 500; SEDA-31, 695; SEDA-32, 777]Thiazolidinediones (glitazones) [SED-15, 3380; SEDA-30, 501; SEDA-31, 697; SEDA-32, 779]Peroxisome proliferator-activated dual receptor agonists [SEDA-32, 782]Chapter 43: Miscellaneous hormonesVasopressin receptor antagonistsVasopressin and analogues [SED-15, 3609; SEDA-30, 511; SEDA-31, 710; SEDA-32, 798]Chapter 44: Drugs that affect lipid metabolismNicotinic acid derivatives [SED-15, 2512; SEDA-32, 815]Chapter 45: Cytostatic and cytotoxic drugsOther cytotoxic drugsChapter 46: Radiological contrast agents and radiopharmaceuticalsMRI contrast mediaUltrasound contrast agents [SED-15, 3543; SEDA-30, 540; SEDA-32, 855]Thorotrast [SED-15, 3401; SEDA-28, 565]Radiopharmaceuticals [SED-15, 3017]Chapter 47: Drugs used in ocular treatmentDrugs used in the management of age-related macular degeneration [SEDA-30, 545; SEDA-31, 739; SEDA-32, 865]Adrenoceptor agonists [SEDA-31, 740; SEDA-32, 869]Anti-glaucoma drugsBeta-adrenoceptor antagonists [SEDA-31, 740; SEDA-32, 870]Carbonic anhydrase inhibitorsGlucocorticosteroids [SED-15, 906; SEDA-30, 548; SEDA-31, 741; SEDA-32, 871]Prostaglandin analogues (see also Chapter 39) [SEDA-32, 871]ProceduresChapter 48: Treatments used in complementary and alternative medicineAsian herbal medicines [SED-15, 1609; SEDA-32, 879]Injectable formulations of chinese medicinesIndian MedicinesSpecific plantsAnimal drugsAcupunctureChiropracticSkin brandingSpa therapyChapter 49: Miscellaneous drugs, materials, medical devices, and techniquesDyestuffsIndex of drugsIndex
